ArticleACR open rheumatology2025
Upregulated GDF-15 in Ankylosing Spondylitis: Pathologic Ossification Promotion through Ligament Fibroblast Osteogenic Differentiation.
Article in ACR open rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The Spleen Promotes Liver Sinusoidal Endothelial Cell Angiogenesis by Stimulating the TGFβ/Smad2/3 Pathway Through GDF15.Journal of gastroenterology and hepatology · 2026Article
- Restoring adenosine balance in axial spondyloarthritis: a stage-specific framework for immune and structural modulation.Frontiers in immunology · 2026Review
- Unveiling GDF-15: a new frontier in combating diabetic osteoporosis.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the role of growth differentiation factor 15 (GDF-15) in ankylosing spondylitis (AS).
methodsA proteoglycan-induced arthritis mouse model was established to mimic the pathologic changes of AS. Expression of GDF-15 in serum and the edge of the vertebral cartilage plate and the spinal entheseal sites in the model group was detected by enzyme-linked immunosorbent assay and immunohistochemistry. Then primary fibroblasts from the ligaments of patients with femoral neck fracture (healthy controls [HC]) and patients with AS were extracted. Western blotting, alkaline phosphatase (ALP) staining and activity assay, and alizarin red staining were used to detect the osteogenic ability of primary fibroblasts.
resultsExpression of GDF-15 was up-regulated in serum and the edge of the vertebral cartilage plate and the spinal entheseal sites in the model group. In vitro, our results showed that GDF-15 promoted the osteogenic differentiation of HC and AS fibroblasts. Furthermore, our results showed that in AS fibroblasts, GDF-15 elevated the expression of osteogenic marker genes (SP7, RUNX2, and COL1) as well as p-glycogen synthase kinase 3β and β-catenin, which are involved in the Wnt/β-catenin signaling pathway. This effect of GDF-15 in AS fibroblasts could be reversed by the inhibitor of the Wnt/β-catenin signaling pathway, DKK-1, suggesting that GDF-15 promoted the osteogenic differentiation of AS fibroblasts via the Wnt/β-catenin signaling pathway. Furthermore, knockdown of GDF-15 also suppressed osteogenic differentiation and inhibited Wnt/β-catenin signaling in AS fibroblasts.
conclusionThis study revealed aberrant up-regulation of GDF-15 in an AS mouse model and osteogenic effect of GDF-15 in AS fibroblasts via the Wnt/β-catenin signaling pathway, which may be one of the mechanisms and therapeutic targets of new bone formation in AS.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.